(UroToday.com) The 2021 European Society of Medical Oncology’s (EMSO) annual congress included a proffered paper session in non-prostate genitourinary tumors, as well as a discussant presentation by Dr. Christian Kollmannsberger discussing decreasing morbidity for the treatment of stage II seminoma. The abstract discussed was “Single-dose carboplatin followed by involved-node radiotherapy as a curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10” by Dr. Alexandros Papachristofilou. Indeed, the price for a cure in testicular cancer is often at the cost of long-term morbidity/mortality from treatment. The SAKK 01/10 trial attempted to decrease treatment burden while maintaining cancer efficacy. This trial is a multicenter, single-arm, phase II study in patients with clinical stage IIA/B seminoma (de novo or relapse on active surveillance). Treatment consisted of 1 cycle carboplatin AUC7 followed by involved-node radiotherapy (IIA: 30 Gy; IIB: 36 Gy) with a primary endpoint of 3-year PFS: